Will Mylan (MYL) Miss this Earnings Season? - Analyst Blog


Shutterstock photo

Mylan Inc. ( MYL ) is set to report fourth quarter and full year 2013 results on Feb 27 before market opens. Last quarter, the company had delivered a positive earnings surprise of 5.13%. Let's see how things are shaping up for this announcement.

Factors at Play

We expect revenues at Mylan, which it reports through two segments (Generics and Specialty), to be hurt by adverse foreign currency movements in the fourth quarter of 2013.

The Specialty segment should continue to perform well driven by strong sales of its flagship product, EpiPen auto-injector (severe allergic reactions). Mylan and Pfizer ( PFE ) have an agreement for EpiPen, under which Pfizer manufactures and Mylan markets the product. The EpiPen Auto-injector is the best prescribed treatment for severe allergic reactions. Sales of the Generics segment, the primary contributor to Mylan's revenues, should be soft due to the adverse impact of foreign currency movements, hurting the overall top line. Prudent cost management will however aid the bottom line.

Earnings Whispers?

Our proven model does not conclusively show that Mylan is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here as you will see below.

Zacks ESP : The Earnings ESP for Mylan is 0.00% since the Most Accurate Estimate stands at 75 cents per share, in line with the Zacks Consensus Estimate.

Zacks Rank : Mylan's Zacks Rank #3 (Hold) when combined with a 0.00% ESP makes surprise prediction difficult.

Stocks to Consider

Here are some companies in the medical sector you may want to consider as our model shows that they have the right combination of elements.

Medivation, Inc. ( MDVN ) has an Earnings ESP of +54.55% and holds a Zacks Rank #2 (Buy). Medivation will be reporting fourth quarter earnings on Feb 27.

Endo Health Solutions ( ENDP ) has an Earnings ESP of +3.19% and holds a Zacks Rank #3. Endo will be reporting fourth quarter earnings on Feb 28.

ENDO PHARMACEUT (ENDP): Free Stock Analysis Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

MYLAN INC (MYL): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Earnings , Stocks
More Headlines for: ENDP , MDVN , MYL , PFE

More from Zacks.com




Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com